Modern Aesthetic Solutions, represented by their Dublin based sub-distributor, Fleetwood Healthcare, has confirmed that it has been awarded an exclusive contract to supply its endovenous radio frequency (EVRF) device across the six Northern Ireland NHS Trusts. Invited to tender against the principal long-standing brands, EVRFcame out top in a combined test of quality and price.
The win comes at a time when many NHS Trusts across the UK and Ireland face mounting pressure to treat all symptomatic varicose veins, in accordance with new guidelines issued by the National Institute for Health and Care Excellence (NICE). Previously, patient referrals were limited to those only with significantly symptomatic veins but the reality is that is it cheaper to treat people when the symptoms first present as opposed to letting them worsen and end up having to treat the ulcerations and other complications which can follow. The new NICE guidelines mean all symptomatic vein sufferers should now be referred for treatment to reduce the cost of the long term treatment pathway. Moreover, they now specify thermal ablation such as that provided by EVRF as the preferred treatment option, recognising it as a safe, reliable and cost saving solution.
The EVRF device, which is exclusive to Modern Aesthetic Solutions in the UK and Ireland, halves the consumable cost per treatment in many cases thanks to its proprietary radio frequency catheter. With around 30,000 procedures of this type carried out on average each year, it is estimated that the EVRF could save the NHS as much as £5 million per annum on the cost of treatment. Since launching to market, Modern Aesthetic Solutions has fielded an increasing number of enquiries from both the public and private sector.
Adam Rubens, Modern Aesthetic Solutions chief executive officer says, “We are absolutely delighted to have secured the supply of radio frequency equipment and catheters to the NHS Trusts across Northern Ireland and we very much hope to continue that trend over the coming months.”
